GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » WuXi XDC Cayman Inc (FRA:L74) » Definitions » Operating Income

WuXi XDC Cayman (FRA:L74) Operating Income : €23.1 Mil (TTM As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is WuXi XDC Cayman Operating Income?

WuXi XDC Cayman's Operating Income for the three months ended in Jun. 2023 was €11.4 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2023 was €23.1 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. WuXi XDC Cayman's Operating Income for the three months ended in Jun. 2023 was €11.4 Mil. WuXi XDC Cayman's Revenue for the three months ended in Jun. 2023 was €65.2 Mil. Therefore, WuXi XDC Cayman's Operating Margin % for the quarter that ended in Jun. 2023 was 17.50%.

WuXi XDC Cayman's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. WuXi XDC Cayman's annualized ROC % for the quarter that ended in Jun. 2023 was 20.41%. WuXi XDC Cayman's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was 46.73%.


WuXi XDC Cayman Operating Income Historical Data

The historical data trend for WuXi XDC Cayman's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi XDC Cayman Operating Income Chart

WuXi XDC Cayman Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Operating Income
4.22 9.82 25.06 41.91

WuXi XDC Cayman Quarterly Data
Dec20 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Dec23
Operating Income Get a 7-Day Free Trial 8.00 - 11.72 11.41 -

WuXi XDC Cayman Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €23.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


WuXi XDC Cayman  (FRA:L74) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

WuXi XDC Cayman's annualized ROC % for the quarter that ended in Jun. 2023 is calculated as:

ROC % (Q: Jun. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2023 ) + Invested Capital (Q: Jun. 2023 ))/ count )
=45.648 * ( 1 - 14.25% )/( (186.581 + 197.046)/ 2 )
=39.14316/191.8135
=20.41 %

where

Invested Capital(Q: Mar. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=351.746 - 110.103 - ( 73.421 - max(0, 136.758 - 191.82+73.421))
=186.581

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=353.14 - 102.576 - ( 72.388 - max(0, 133.893 - 187.411+72.388))
=197.046

Note: The Operating Income data used here is four times the quarterly (Jun. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

WuXi XDC Cayman's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2023  Q: Jun. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=58.116/( ( (120.872 + max(-17.485, 0)) + (127.865 + max(-22.38, 0)) )/ 2 )
=58.116/( ( 120.872 + 127.865 )/ 2 )
=58.116/124.3685
=46.73 %

where Working Capital is:

Working Capital(Q: Mar. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(89.684 + 8.093 + 17.554) - (110.103 + 0 + 22.713)
=-17.485

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(86.7 + 6.11 + 18.339) - (102.576 + 0 + 30.953)
=-22.38

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

WuXi XDC Cayman's Operating Margin % for the quarter that ended in Jun. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Jun. 2023 )/Revenue (Q: Jun. 2023 )
=11.412/65.2
=17.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


WuXi XDC Cayman Operating Income Related Terms

Thank you for viewing the detailed overview of WuXi XDC Cayman's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


WuXi XDC Cayman (FRA:L74) Business Description

Comparable Companies
Traded in Other Exchanges
Address
No. 11 Xinhui Ring Road, Xinwu, Jiangsu, Wuxi, CHN
Website
WuXi XDC Cayman Inc is a leading CRDMO focused on the global ADC and broader bioconjugate market and the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, It offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development and manufacturing. The company provides these services from proximately located, state-of-the-art laboratories and manufacturing facilities, leading to the significant reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development and manufacturing platform, its mission is to continuously enhance its platform, and propel and transform the development of the bioconjugate industry.

WuXi XDC Cayman (FRA:L74) Headlines

No Headlines